Amlodipine And Atorvastatin Tablet, Film Coated
Product Images NDC 72162-2092

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Amlodipine And Atorvastatin (NDC 72162-2092). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Amlodipine Besylate And Atorvastatin Calcium 02)

A Kaplan-Meier event rate curve comparing Amlodipine and Placebo over 24 months. The graph shows cumulative event rates on the y-axis and time in months on the x-axis, with Amlodipine demonstrating a lower event rate than Placebo. The figure includes a P-value of 0.003, a hazard ratio of 0.691, and a 95% confidence interval from 0.54 to 0.88.*

FDA Label Image

Figure 2 (Amlodipine Besylate And Atorvastatin Calcium 03)

A forest plot illustrating the hazard ratios with 95% confidence intervals comparing the effects of Amlodipine versus placebo in various patient subgroups based on age, gender, baseline sitting systolic blood pressure, baseline vessel disease status, baseline vessel stenosis, and PCI-stent strata. The plot shows effect estimates favoring Amlodipine on the left side and placebo on the right side of the vertical reference line at 1.0.*

FDA Label Image

Figure 3 (Amlodipine Besylate And Atorvastatin Calcium 04)

A line chart comparing cumulative incidence (%) over time (years) between Atorvastatin and placebo groups. The chart shows lower cumulative incidence for Atorvastatin compared to placebo, with accompanying hazard ratio and p-value indicated.*

FDA Label Image

Figure 4 (Amlodipine Besylate And Atorvastatin Calcium 05)

A cumulative hazard plot comparing the time to first primary endpoint over four years of follow-up for patients taking Atorvastatin versus placebo. The graph shows lower cumulative hazard percentages for Atorvastatin relative to placebo, with hazard ratio (HR) 0.63 (0.48-0.83) and p-value 0.001 indicating statistical analysis of event rates over time.*

FDA Label Image

Figure 5 (Amlodipine Besylate And Atorvastatin Calcium 06)

A line graph showing the percentage of subjects experiencing a major cardiovascular event over time in years up to 5 years. Two lines compare Atorvastatin doses: 10 mg (dashed) and 80 mg (solid). The graph includes a hazard ratio (HR 0.78) with confidence intervals and a p-value indicating statistical significance.*

FDA Label Image

Amlodipine (Amlodipine)

Chemical structure diagram showing the molecular formula of Amlodipine and Atorvastatin, the active ingredients in the drug product. The diagram displays atomic connections, including aromatic rings and functional groups with chlorine, sulfonic acid, and methoxy substituents.*

FDA Label Image

Atorvastatin-glycol-solvate (Atorvastatin Glycol Solvate)

Chemical structure of Amlodipine and Atorvastatin as shown in the image. The diagram includes the molecular structures with elemental atoms and bonds labeled, highlighting atorvastatin calcium salt and associated components.*

FDA Label Image

Label (Lbl721622092)

Label for Amlodipine and Atorvastatin Tablets, USP, film-coated oral tablets with strengths 5 mg of Amlodipine and 10 mg of Atorvastatin. The package contains 30 tablets. Labeler is Bryant Ranch Prepack, and the product is manufactured by Apotex Inc. The label includes storage instructions and safety warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.